Free Trial
Ends Tomorrow! Last Chance to Save $100 on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim $100 Off
Claim MarketBeat All Access Sale Promotion

Cassava Sciences (FLNA) Competitors

Cassava Sciences logo
$1.31 +0.02 (+1.55%)
As of 05/22/2026 04:00 PM Eastern

FLNA vs. HELP, ALEC, NERV, CHRS, and CNTN

Should you buy Cassava Sciences stock or one of its competitors? MarketBeat compares Cassava Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cassava Sciences include Cybin (HELP), Alector (ALEC), Minerva Neurosciences (NERV), Coherus Oncology (CHRS), and Hillstream Biopharma (CNTN). These companies are all part of the "pharmaceutical products" industry.

How does Cassava Sciences compare to Cybin?

Cassava Sciences (NASDAQ:FLNA) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Cybin'saverage media sentiment score.

Company Overall Sentiment
Cassava Sciences Neutral
Cybin Neutral

Cybin has a consensus price target of $58.75, indicating a potential upside of 1,155.34%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Cassava Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cybin
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cassava Sciences has a beta of -0.75, meaning that its share price is 175% less volatile than the broader market. Comparatively, Cybin has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Cassava Sciences' return on equity of -53.90% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -53.90% -34.20%
Cybin N/A -59.98%-50.80%

Cybin is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$1.61N/A
CybinN/AN/A-$81.31M-$4.23N/A

Summary

Cybin beats Cassava Sciences on 6 of the 11 factors compared between the two stocks.

How does Cassava Sciences compare to Alector?

Alector (NASDAQ:ALEC) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

85.8% of Alector shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 8.3% of Alector shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alector has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market.

Cassava Sciences has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.05M11.66-$142.93M-$1.19N/A
Cassava SciencesN/AN/A-$90.97M-$1.61N/A

In the previous week, Alector's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company Overall Sentiment
Alector Neutral
Cassava Sciences Neutral

Cassava Sciences has a net margin of 0.00% compared to Alector's net margin of -680.83%. Cassava Sciences' return on equity of -53.90% beat Alector's return on equity.

Company Net Margins Return on Equity Return on Assets
Alector-680.83% -295.17% -40.95%
Cassava Sciences N/A -53.90%-34.20%

Alector currently has a consensus target price of $3.63, indicating a potential upside of 64.03%. Given Alector's stronger consensus rating and higher possible upside, research analysts plainly believe Alector is more favorable than Cassava Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alector
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Alector beats Cassava Sciences on 8 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 10.4% of Minerva Neurosciences shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Minerva Neurosciences had 11 more articles in the media than Cassava Sciences. MarketBeat recorded 11 mentions for Minerva Neurosciences and 0 mentions for Cassava Sciences. Minerva Neurosciences' average media sentiment score of 0.74 beat Cassava Sciences' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company Overall Sentiment
Minerva Neurosciences Positive
Cassava Sciences Neutral

Minerva Neurosciences currently has a consensus target price of $10.50, suggesting a potential upside of 99.62%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Minerva Neurosciences is more favorable than Cassava Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Neurosciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Minerva Neurosciences has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market.

Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A-$293.42M-$29.16N/A
Cassava SciencesN/AN/A-$90.97M-$1.61N/A

Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Minerva NeurosciencesN/A N/A -32.63%
Cassava Sciences N/A -53.90%-34.20%

Summary

Minerva Neurosciences beats Cassava Sciences on 10 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Coherus Oncology presently has a consensus target price of $8.67, indicating a potential upside of 438.30%. Given Coherus Oncology's stronger consensus rating and higher probable upside, research analysts plainly believe Coherus Oncology is more favorable than Cassava Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coherus Oncology
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Coherus Oncology's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company Overall Sentiment
Coherus Oncology Neutral
Cassava Sciences Neutral

Coherus Oncology has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market.

Coherus Oncology has a net margin of 397.30% compared to Cassava Sciences' net margin of 0.00%. Cassava Sciences' return on equity of -53.90% beat Coherus Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Coherus Oncology397.30% -198.90% -46.65%
Cassava Sciences N/A -53.90%-34.20%

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Coherus Oncology has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus Oncology$42.17M5.89$168.02M$1.670.96
Cassava SciencesN/AN/A-$90.97M-$1.61N/A

Summary

Coherus Oncology beats Cassava Sciences on 11 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Cassava Sciences (NASDAQ:FLNA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

In the previous week, Hillstream Biopharma had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Hillstream Biopharma and 0 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.00 beat Hillstream Biopharma's score of -0.18 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Hillstream Biopharma Neutral
Cassava Sciences Neutral

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hillstream BiopharmaN/AN/A-$35.92M-$1.15N/A
Cassava SciencesN/AN/A-$90.97M-$1.61N/A

Hillstream Biopharma has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, meaning that its stock price is 175% less volatile than the broader market.

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Hillstream Biopharma's return on equity of -31.50% beat Cassava Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Hillstream BiopharmaN/A -31.50% -24.72%
Cassava Sciences N/A -53.90%-34.20%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hillstream Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Hillstream Biopharma beats Cassava Sciences on 7 of the 10 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for FLNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FLNA vs. The Competition

MetricCassava SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$63.28M$3.04B$6.44B$12.34B
Dividend YieldN/A1.97%2.76%5.28%
P/E Ratio-0.8118.0421.2625.66
Price / SalesN/A358.13556.8487.32
Price / CashN/A57.7443.6856.73
Price / Book0.935.8610.367.14
Net Income-$90.97M$74.99M$3.56B$335.80M
7 Day Performance11.02%0.37%5.12%3.02%
1 Month Performance-18.63%-2.99%3.54%2.48%
1 Year Performance-37.91%34.38%34.14%35.08%

Cassava Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FLNA
Cassava Sciences
0.132 of 5 stars
$1.31
+1.6%
N/A-37.9%$63.28MN/AN/A20
HELP
Cybin
3.1209 of 5 stars
$4.54
-2.8%
$58.75
+1,194.1%
N/A$234.40MN/AN/A50
ALEC
Alector
3.0948 of 5 stars
$2.11
-2.5%
$3.63
+72.2%
+78.2%$233.72M$21.05MN/A270
NERV
Minerva Neurosciences
2.5725 of 5 stars
$4.99
-4.3%
$10.50
+110.5%
+260.3%$232.34MN/AN/A9
CHRS
Coherus Oncology
2.5423 of 5 stars
$1.51
-4.1%
$8.67
+475.9%
+112.9%$232.15M$42.17M0.90330

Related Companies and Tools


This page (NASDAQ:FLNA) was last updated on 5/24/2026 by MarketBeat.com Staff.
From Our Partners